Please assess the completion status of the following clinical trial:

Trial Title: Peanut Oral Immunotherapy in Children: IMPACT Follow Up Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Patients who meet all of the following criteria are eligible for enrollment as study participants, including participants who:~* Subjects who were randomized to the placebo arm of protocol NA_00077852 Oral Immunotherapy for Induction of Tolerance in Peanut Allergic Children.~* Parent guardian must be able to understand and provide informed consent~* Peanut allergy, as defined by a reaction to a cumulative dose of ≤1000 mg of peanut protein during the End-of-Treatment food challenge from Protocol NA_00077852 Oral Immunotherapy for Induction of Tolerance in Peanut Allergic Children~Exclusion Criteria:~Patients who meet any of these criteria are not eligible for enrollment as study participants, including participants who:~* Inability or unwillingness of a parent guardian to give written informed consent or comply with study protocol~* History of severe anaphylaxis to peanut, defined by severe hypoxia, hypotension, neurological compromise, confusion, cardiovascular collapse, or loss of consciousness~* Significant chronic disease (other than asthma, rhinitis, or atopic dermatitis) requiring therapy; e.g., heart disease or cystic fibrosis which is judged by the investigator to have potential impact on study outcomes or safety.~* Severe or poorly controlled atopic dermatitis per investigator's discretion~* Past or current history of eosinophilic gastrointestinal disease~* Diagnosis of asthma that meets any of the following criteria:~  * Uncontrolled asthma (as per Global Initiative for Asthma \[GINA\] latest guidelines)~ * History of 2 or more systemic corticosteroid courses or 1 systemic course within the 3 previous months prior to visit 1 for treating wheezing~ * Prior intubation/mechanical ventilation for asthma~* Currently receiving β-blocking agents, angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, calcium channel blockers or tricyclic antidepressant therapy.~* Current participation in another clinical trial or participation in another clinical trial in the last 90 days

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 9 Years
- Healthy Volunteers: f

Study Arms:
- Peanut Flour: Open label peanut OIT (Type: EXPERIMENTAL): This is an open label treatment for subjects who had previously received placebo treatment in a prior peanut OIT study

Based on this trial design, predict the completion outcome and termination type (if applicable).